Advanced search
Publication Cover
Journal of Blood Medicine Volume 10, 2019 - Issue
Submit an article Journal homepage
108
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

Mindy L Simpson1 Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, IL, USACorrespondence[email protected]
View further author information
,
Roshni Kulkarni2 Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USAView further author information
,
Carmen Escuriola Ettingshausen3 HZRM – Haemophilia Centre Rhein-Main, Frankfurt-Mörfelden, Mörfelden-Walldorf, GermanyView further author information
,
Rikke Medom Meldgaard4 Novo Nordisk A/S, Søborg, DenmarkView further author information
,
David L Cooper5 Novo Nordisk Inc, Plainsboro, NJ, USAORCID Iconhttps://orcid.org/0000-0002-4499-1526View further author information
ORCID Icon &
Robert Klamroth6 Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum, Berlin, GermanyView further author information
Pages 391-398 | Published online: 13 Nov 2019

References

  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47. doi:10.1111/j.1365-2516.2012.02909.x22776238
  • American Thrombosis & Hemostasis Network. Factor IX Deficiency. Research Report. American Thrombosis & Hemostasis Network; 2018.
  • den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44. doi:10.1111/j.1365-2516.2010.02383.x20825504
  • Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018;2(16):2136–2144. doi:10.1182/bloodadvances.201802055230143528
  • Shire. RIXUBIS prescribing information. Available from: https://www.shirecontent.com/PI/PDFs/RIXUBIS_USA_ENG.pdf Accessed 325, 2019.
  • Pfizer Inc. BENEFIX prescribing information. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=492 Accessed 325, 2019.
  • Aptevo BioTherapeutics LLC. IXINITY prescribing information. Available from: https://www.ixinity.com/sites/default/files/IXINITY_PI_Aptevo.pdf Accessed 325, 2019.
  • Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600–3606. doi:10.1182/blood.v98.13.360011739163
  • Ragni MV, Pasi KJ, White GC, et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia. 2002;8(2):91–97.11952843
  • Quon DV, Logan L. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Haemophilia. 2011;17(1):e196–e201. doi:10.1111/j.1365-2516.2010.02354.x20618876
  • Escuriola Ettingshausen C, Hegemann I, Simpson ML, et al. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial. Res Pract Thromb Haemost. 2019;3(2):268–276. doi:10.1002/rth2.1219231011711
  • Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695–2701. doi:10.1182/blood-2011-02-33559621555744
  • Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119(3):666–672. doi:10.1182/blood-2011-07-36700322110246
  • Collins PW, Moss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. 2012;10(11):2305–2312. doi:10.1111/jth.1200022998153
  • Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880–3886. doi:10.1182/blood-2014-05-57305525261199
  • Diao L, Li S, Ludden T, et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53(5):467–477. doi:10.1007/s40262-013-0129-724452809
  • Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa06765917687129
  • Escobar MA, Tehranchi R, Karim FA, et al. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017;23(1):67–76. doi:10.1111/hae.1304127480487
  • Powell JS, Apte S, Chambost H, et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015;168(1):124–134. doi:10.1111/bjh.1311225208598

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.